Highlighting its commitment to RNA therapeutics, Genentech has partnered with Ribometrix to develop RNA-targeted small molecule therapeutics against several targets. Research from Ribometrix has shown that many RNAs implicated in disease contain structural pockets, which can be targeted with small molecules. The deal, which is worth up to US$1 B, comes less than a year after Roche signed a similar deal with Arrakis Therapeutics.